VentiRx Pharmaceuticals Inc. (VentiRx)

Oncology Corporate Profile

HQ Location

1191 Second Avenue, Suite 1105
Seattle, WA 98101

Company Description

VentiRx Pharmaceuticals Inc. is a clinical stage biopharmaceutical company committed to the development and commercialization of novel Toll-like receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory and inflammatory diseases. The Company's lead product candidate is VTX-2337, a small molecule TLR8 agonist for the treatment of cancer. VentiRx has an exclusive, world-wide collaboration with Celgene Corporation for VTX-2337. VentiRx is a privately held organization based in Seattle, Washington.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
motolimod / VTX-2337toll-like Receptor 8 (TLR8)Ovarian cancerII
motolimod / VTX-2337toll-like Receptor 8 (TLR8)Squamous cell cancer of the head and neck (SCCHN)II

View additional information on product candidates here »


Recent News Headlines

There are no news items to display